Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | DTYMK | P23919 | 2/20 | 0.39 |
| ▸ | STS | P08842 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16122859 | 0.73 | TP53 (0.55) | BLMTP53RAB9AMAPTTHRB | |
| SCHEMBL16122889 | 0.72 | DTYMK (0.49) | MEN1KMT2APOLBDTYMKSTS | |
| SCHEMBL4844156 | 0.70 | GPR119 (0.55) | RAB9AMAPTDTYMKSTSALDH1A1 | |
| SCHEMBL15337783 | 0.69 | KRAS (0.47) | RAB9AMEN1KMT2AMAPTPOLB | |
| SCHEMBL16098893 | 0.69 | MEN1 (0.43) | MEN1KMT2APOLBDTYMKSTS | |
| SCHEMBL16102324 | 0.66 | GAA (0.44) | MEN1KMT2AMAPTPOLBSTS | |
| SCHEMBL24095092 | 0.66 | KMT2A (0.61) | MEN1KMT2A | |
| SCHEMBL16122826 | 0.65 | KRAS (0.50) | TP53MEN1KMT2ASTSGAA | |
| SCHEMBL30642270 | 0.65 | KRAS (0.50) | TP53MEN1KMT2ASTSGAA | |
| SCHEMBL2384235 | 0.65 | POLB (0.48) | MEN1KMT2AMAPTPOLBSTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3401314-B1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10273207-B2 | Covalent inhibitors of kras G12C | ARAXES PHARMA LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
| US-9926267-B2 | Covalent inhibitors of K-Ras G12C | ARAXES PHARMA LLC (US) | 2018-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | BLM 827/4885TP53 7/4885RAB9A 83/4885 |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | KRAS, NRAS, HRAS | BLM 827/4885TP53 7/4885RAB9A 83/4885 |
| US-10273207-B2 | Covalent inhibitors of kras G12C | KRAS, NRAS, HRAS | BLM 827/4885TP53 7/4885RAB9A 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.